fromInsideHook1 week agoCompounding Breaks Up Novo Nordisk-Hims & Hers PartnershipAs GLP-1 drugs like Wegovy and Ozempic grow in popularity, compounded alternatives have emerged, leading to safety concerns and regulatory scrutiny.Health
Growth hackingfrom24/7 Wall St.4 months agoHIMS Stock Craters - Is It a Buying Opportunity?Hims & Hers Health faces challenges after the FDA resolved the semaglutide shortage, impacting their growth from compounding drug sales.
Tech industryfrom24/7 Wall St.4 months agoMarkets Today: Dow Down, HD Rises, HIMS SinksWeaker consumer confidence has undermined market gains, despite some strong earnings from Home Depot.
from24/7 Wall St.3 weeks agoGrowth hackingBought $40,000 of Hims & Hers (HIMS) Stock on a YOLO - Is it Time to Sell?
from24/7 Wall St.2 weeks agoNYC startupS&P 500 (NYSEARCA: SPY) Live: Markets Turn Higher in Face of Heightened Mideast Tensions
Growth hackingfrom24/7 Wall St.4 months agoHIMS Stock Craters - Is It a Buying Opportunity?Hims & Hers Health faces challenges after the FDA resolved the semaglutide shortage, impacting their growth from compounding drug sales.
Tech industryfrom24/7 Wall St.4 months agoMarkets Today: Dow Down, HD Rises, HIMS SinksWeaker consumer confidence has undermined market gains, despite some strong earnings from Home Depot.
from24/7 Wall St.3 weeks agoGrowth hackingBought $40,000 of Hims & Hers (HIMS) Stock on a YOLO - Is it Time to Sell?
from24/7 Wall St.2 weeks agoNYC startupS&P 500 (NYSEARCA: SPY) Live: Markets Turn Higher in Face of Heightened Mideast Tensions
HealthcarefromFast Company4 months agoHims & Hers stock surges 23%: Telehealth company announces expansion into blood testing weeks after Super Bowl buzzHims & Hers is expanding into at-home blood testing to enhance personal healthcare through technology.
NYC startupfromSFGATE3 months agoBay Area startup, a few years after being bought for $131M, shuts downApostrophe is shutting down to streamline dermatology services under Hims & Hers.
MiscellaneousfromFast Company4 months agoHims & Hers markets itself in a very 2025 way: by picking a fightHims & Hers targets Big Pharma with a Super Bowl ad promoting a cheaper weight-loss drug, reflecting anti-establishment sentiments.
HealthcarefromFast Company4 months agoHims & Hers stock surges 23%: Telehealth company announces expansion into blood testing weeks after Super Bowl buzzHims & Hers is expanding into at-home blood testing to enhance personal healthcare through technology.
NYC startupfromSFGATE3 months agoBay Area startup, a few years after being bought for $131M, shuts downApostrophe is shutting down to streamline dermatology services under Hims & Hers.
MiscellaneousfromFast Company4 months agoHims & Hers markets itself in a very 2025 way: by picking a fightHims & Hers targets Big Pharma with a Super Bowl ad promoting a cheaper weight-loss drug, reflecting anti-establishment sentiments.
